Farhatullah Syed
Overview
Explore the profile of Farhatullah Syed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Georgiadis C, Nickolay L, Syed F, Zhan H, Gkazi S, Etuk A, et al.
Haematologica
. 2024 Jul;
109(12):3941-3951.
PMID: 38988258
Umbilical cord blood (UCB) T cells exhibit distinct naïve ontogenetic profiles and may be an attractive source of starting cells for the production of chimeric antigen receptor (CAR) T cells....
2.
Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi S, et al.
N Engl J Med
. 2023 Jun;
389(10):899-910.
PMID: 37314354
Background: Cytidine deamination that is guided by clustered regularly interspaced short palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide into another - specifically, cytosine to thymine...
3.
Syed F, El Fakih R, Alahmari A, Osman Ali A, Aljurf M
Hematol Oncol Stem Cell Ther
. 2022 Nov;
15(3):137-152.
PMID: 36395497
Increasing success of adaptive cell therapy (ACT), such as genetically engineered T cells to express chimeric antigen receptors (CARs) proven to be highly significant technological advancements and impressive clinical outcomes...
4.
Ottaviano G, Georgiadis C, Gkazi S, Syed F, Zhan H, Etuk A, et al.
Sci Transl Med
. 2022 Oct;
14(668):eabq3010.
PMID: 36288281
Genome editing of allogeneic T cells can provide "off-the-shelf" alternatives to autologous chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain (TRAC) to prevent graft-versus-host...
5.
Tagalakis A, Jayarajan V, Maeshima R, Ho K, Syed F, Wu L, et al.
Adv Funct Mater
. 2022 Jun;
31(37):2104843.
PMID: 35712226
The authors aim to develop siRNA therapeutics for cancer that can be administered systemically to target tumors and retard their growth. The efficacy of systemic delivery of siRNA to tumors...
6.
Di W, Lwin S, Petrova A, Bernadis C, Syed F, Farzaneh F, et al.
Hum Gene Ther
. 2019 Jul;
30(9):1067-1078.
PMID: 31288584
Netherton syndrome (NS) is a rare autosomal recessive skin disorder caused by mutations in . It is a debilitating condition with notable mortality in the early years of life. There...
7.
Lwin S, Syed F, Di W, Kadiyirire T, Liu L, Guy A, et al.
JCI Insight
. 2019 Jun;
4(11).
PMID: 31167965
BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) is a severe form of skin fragility disorder due to mutations in COL7A1 encoding basement membrane type VII collagen (C7), the main constituent of anchoring...
8.
Bagabir R, Syed F, Shenjere P, Paus R, Bayat A
J Invest Dermatol
. 2016 Jul;
136(11):2319-2323.
PMID: 27424317
No abstract available.
9.
Georgiadis C, Syed F, Petrova A, Abdul-Wahab A, Lwin S, Farzaneh F, et al.
J Invest Dermatol
. 2016 Jan;
136(1):284-92.
PMID: 26763448
Cells therapies, engineered to secrete replacement proteins, are being developed to ameliorate otherwise debilitating diseases. Recessive dystrophic epidermolysis bullosa (RDEB) is caused by defects of type VII collagen, a protein...
10.
Record J, Malinova D, Zenner H, Plagnol V, Nowak K, Syed F, et al.
Blood
. 2015 Jul;
126(13):1527-35.
PMID: 26224645
Megakaryoblastic leukemia 1 (MKL1), also known as MAL or myocardin-related transcription factor A (MRTF-A), is a coactivator of serum response factor, which regulates transcription of actin and actin cytoskeleton-related genes....